Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook
This article was originally published in PharmAsia News
TOKYO - Having no large extra charges for acquisitions like its Japanese competitors, Astellas Pharma predicted Nov. 5 revenues and earnings for fiscal 2008 would be slightly better than its earlier forecast but the yen's appreciation and slow new drug launches would nudge the performance modestly lower than in the preceding business year
You may also be interested in...
TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference
Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia
Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients